Brokerages predict that Novavax, Inc. (NASDAQ:NVAX) will announce sales of $4.40 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Novavax’s earnings, with the lowest sales estimate coming in at $4.00 million and the highest estimate coming in at $4.80 million. Novavax reported sales of $7.74 million during the same quarter last year, which indicates a negative year-over-year growth rate of 43.2%. The company is expected to announce its next quarterly earnings report on Wednesday, November 6th.

On average, analysts expect that Novavax will report full-year sales of $10.64 million for the current fiscal year, with estimates ranging from $5.20 million to $15.30 million. For the next fiscal year, analysts anticipate that the business will report sales of $12.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Novavax.

Novavax (NASDAQ:NVAX) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.61) by ($0.08). The company had revenue of $3.36 million during the quarter, compared to analysts’ expectations of $3.53 million. During the same period in the prior year, the firm earned ($2.40) EPS.

Several equities research analysts have commented on NVAX shares. Oppenheimer upped their price target on Novavax from $1.25 to $25.00 in a research note on Monday, May 13th. ValuEngine upgraded Novavax from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Cantor Fitzgerald restated a “hold” rating on shares of Novavax in a research note on Thursday, May 9th. Zacks Investment Research upgraded Novavax from a “hold” rating to a “buy” rating and set a $8.00 price target for the company in a research note on Thursday, May 16th. Finally, Chardan Capital restated a “neutral” rating and set a $7.00 price target on shares of Novavax in a research note on Friday, May 10th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. Novavax currently has an average rating of “Hold” and an average price target of $40.70.

NASDAQ:NVAX traded up $1.80 on Friday, hitting $6.10. 6,025,358 shares of the stock were exchanged, compared to its average volume of 770,728. The stock has a market capitalization of $102.87 million, a PE ratio of -0.61 and a beta of 2.21. The business has a fifty day moving average of $4.78. Novavax has a fifty-two week low of $4.01 and a fifty-two week high of $51.60.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC boosted its position in shares of Novavax by 127.8% in the fourth quarter. Millennium Management LLC now owns 2,934,275 shares of the biopharmaceutical company’s stock worth $5,399,000 after buying an additional 1,645,934 shares during the period. Edmond DE Rothschild Holding S.A. boosted its holdings in Novavax by 86.7% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 1,537,130 shares of the biopharmaceutical company’s stock valued at $847,000 after purchasing an additional 713,752 shares during the last quarter. Creative Planning boosted its holdings in Novavax by 161.7% in the first quarter. Creative Planning now owns 513,324 shares of the biopharmaceutical company’s stock valued at $283,000 after purchasing an additional 317,204 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Novavax by 3,799.2% in the first quarter. SG Americas Securities LLC now owns 435,107 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 423,948 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its holdings in Novavax by 296.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 137,288 shares of the biopharmaceutical company’s stock valued at $253,000 after purchasing an additional 102,657 shares during the last quarter.

Novavax Company Profile

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

See Also: How to Profit and Limit Losses With Stop Orders

Get a free copy of the Zacks research report on Novavax (NVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.